WestPark Capital Initiates Akebia Therapeutics Coverage With Buy Rating

WestPark Capital initiated coverage of Akebia Therapeutics (NASDAQCM:AKBA) with a Buy recommendation on September 8, 2026, adding a new voice to a Street that has grown increasingly divided on the kidney-disease biopharma’s near-term trajectory. The initiation arrives as the stock trades near multi-month lows following a sharp August pullback, with shares closing at $0.97 on September 4 — up 10.94% from the prior week’s $0.88 close but still down 26.16% from the $1.32 level recorded on August 4.

Coverage Initiation Adds to a Shifting Consensus

WestPark’s Buy rating brings the total number of analysts covering Akebia to 11, according to Fintel data. The broader consensus has softened notably over the past month. As of September 1, the breakdown stood at 4 strong buy, 5 buy, and 2 hold ratings — translating to 81.8% positive recommendations. That compares with the August 1 period, which showed 5 strong buy, 5 buy, and 1 hold, or 90.9% positive.

Also read: TechnipFMC Shares Cross Average Analyst Target: What the Ratings Signal

The shift mirrors a downward revision in price targets. The consensus mean target fell to $3.88 as of August 28, down 9.52% from the $4.28 mean recorded on August 4. Even at the reduced level, the mean target implies roughly 300% upside from the current share price — a wide gap that reflects the market’s skepticism about near-term catalysts versus the Street’s longer-term modeling.

Business Fundamentals and Recent Earnings

Akebia’s core commercial asset remains Auryxia (ferric citrate), approved for controlling serum phosphorus levels in chronic kidney disease patients on dialysis and for treating iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. The company’s most recent earnings report, posted on August 5, showed an actual EPS of -$0.03, beating the consensus estimate of -$0.0449. Revenue came in at $49.1 billion against an estimated $49.8 billion — a slight miss on the top line that may have contributed to the subsequent selloff.

Also read: Xcel Energy's $70B Capital Plan: A Closer Look at the Growth Strategy

The company operates in a competitive segment of the nephrology market, facing pressure from both established phosphate binders and newer entrants targeting anemia of chronic kidney disease. Auryxia’s differentiated dual indication — covering both phosphorus control and iron deficiency anemia — remains a key part of the investment thesis for bulls, but commercial execution and reimbursement dynamics have historically created volatility in quarterly results.

What the Buy Rating Signals for Investors

WestPark’s initiation at this price level suggests the firm sees asymmetric risk/reward at roughly $0.97 per share. The timing is notable: initiating coverage after a 26% monthly decline allows the firm to establish a position thesis at a valuation that already reflects considerable pessimism.

For existing shareholders, the key question is whether the analyst community’s price targets — still clustered well above $3.00 — reflect realistic upside or simply lag the market’s reassessment of Akebia’s growth prospects. The narrowing of positive recommendations from 90.9% to 81.8% over the past month indicates that at least one analyst has tempered their enthusiasm, even as the overall tone remains constructive.

Investors should also watch for upcoming clinical and regulatory milestones that could serve as catalysts. Akebia’s pipeline beyond Auryxia, including vadadustat for anemia due to chronic kidney disease, has faced regulatory hurdles in the U.S. market, though the drug received approval in other jurisdictions. Any updates on that front could materially alter the stock’s trajectory.

With the stock trading at a significant discount to the consensus target, the coming quarters will test whether WestPark’s bullish stance proves prescient or whether the broader market’s caution reflects challenges not fully captured in analyst models. The next earnings report, expected in early November, will provide the first concrete check on commercial trends since this coverage initiation.

This article is for informational purposes only and does not constitute financial advice. Stock markets are volatile and speculative; investors should conduct their own research and consult with a qualified financial advisor before making investment decisions.

Written by

Benjamin

Benjamin Carter covers business, finance, and the stock market for StockPil, focusing on the trends and data that matter to everyday investors.

Source: Nasdaq